TRIAL DETAIL
Phase I, Combining Oral Topotecan With Oral Pazopanib
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Phase I, Combining Oral Topotecan With Oral Pazopanib |
|||
NCT#: |
||||
Conditions: |
Any type of Cancer |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 09/01/2008 |
Age of Trial (yrs) 16.6 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor + topoisomerase inhibitor |
|||
Strategy: |
Block KIT + Unblock cell death genes |
|||
Trial Type: |
GIST not specified. GIST patients known to be enrolled. |
|||
Other Protocol IDs: |
HYT109091 |
|||
Sponsor: |
GlaxoSmithKline |
|||
Patient Contact: |
US GSK Clinical Trials Call Center
|
|||
Contact email: |
||||
Contact Phone: |
877-379-3718 |
|||
Randomized: |
||||
IV or Oral: |
||||
Trial Notes: |
This is a phase I trial to test the safety and maximum tolerated dose of the combination of pazopanib (Vortrient) and Toptecan. |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Amsterdam |
1066 CX |
Netherlands |
|||
Heidelberglaan 100 |
Utrecht |
3584 CX |
Netherlands |
||
38th and Walnut Streets |
Philadelphia |
PA |
19104 |
USA |